The TBX1 gene is haploinsufficient in the 22q11.2 deletion syndrome (22q11.2DS), and genetic evidence from human patients and mouse models points to a major role of this gene in the pathogenesis of this syndrome. Tbx1 can activate and repress transcription and previous work has shown that one of its functions is to negatively modulate cardiomyocyte differentiation. Tbx1 occupies the anterior heart field (AHF) enhancer of the Mef2c gene, which encodes a key cardiac differentiation transcription factor. Here we show that increased dosage of Tbx1 is associated with down regulation of Mef2c expression and reduced acetylation of its AHF enhancer in cultured mouse myoblasts. Consistently, 22q11.2DS-derived and in vitro differentiated induced pluripotent stem cells (hiPSCs) expressed higher levels of Mef2c and showed increased AHF acetylation, compared to hiPSCs from a healthy donor.
Introduction
During development, cardiac progenitors of the second heart field (SHF) are recruited or incorporated into the cardiac outflow tract and right ventricle (Kelly, 2012) . During this process, cells activate a differentiation program that leads to expression of specialized proteins such as contractile proteins necessary for cardiomyocyte function. This process, still to be dissected in detail, should be tightly regulated so that a sufficient number of progenitors are allowed to proliferate and are prevented from differentiating prematurely. These two basic functions (pro-proliferative and anti-differentiative) are likely effected by a combination of signals and transcription factors, among the latters, Tbx1 is a major candidate (Baldini et al., 2017) . Indeed, it is expressed in cardiac progenitors of the SHF, is shut down as they start differentiating, and it regulates positively pro-proliferative signals, and, negatively, prodifferentiative factors. Among the latters there are Gata4 (Liao et al., 2008; Pane et al., 2012) ,
Mef2c (Pane et al., 2012) , SRF (Chen et al., 2009) , and Smad1 . Down regulation of Srf and Smad1 signaling are effected through non-transcriptional mechanisms, but
Mef2c gene expression appears to be transcriptionally repressed by Tbx1.
Tbx1 regulates its target genes by interacting with the SWI-SNF-like BAF complex and with histone methyltransferases (Chen et al., 2012; Fulcoli et al., 2016; Stoller et al., 2010) .
However, there are a number of question marks to be answered, for example what are the cofactors that determine whether a target gene is up or down regulated. In this work, we addressed the question as to how Tbx1 represses Mef2c expression. We used mouse myoblast cells, transgenic mouse embryos, and differentiating human induced pluripotent stem cells (hiPSCs) from a 22q11.2DS patient and a healthy donor. Results, indicate that transcriptional repression is associated with reduced histone 3 acetylation in the region bound by Tbx1 in cultured cells, that is the previously defined AHF enhancer of the Mef2c gene (Dodou et al., 2004) . In addition, we show that in vivo, Tbx1 regulation of the AHF enhancer is dosagedependent and is regionally restricted, suggesting that there are crucial interactions with other transcription factors in regulating this enhancer.
Materials and Methods

Generation of human induced pluripotent stem cells (hiPSCs)
Neonatal skin fibroblasts from a 22q11.2DS/DiGeorge syndrome patient were obtained from the Coriell Institute (GM07215); control skin fibroblasts were obtained from an unrelated age-and gender-matched anonimous, healthy donor.
For iPSC induction, retroviruses encoding the human OCT3/4, SOX2, KLF4, and c-MYC factors were independently produced by transfecting HEK293T cells with pMXs vectors (Addgene plasmids 17217, 17218, 17219, and 17220) and the combination of moloney gag-pol plasmid pUMVC (Addgene plasmid 8449) and VSV envelope plasmid (Addgene plasmid 8454) in DMEM containing 10% FBS using Fugene HD (Roche). Viral supernatants were harvested after 48 and 72 h, filtered through a 0.45-μm low-protein-binding cellulose acetate filter, concentrated by a spin column (Millipore, Billerica, MA, USA), and used directly to infect twice (24 h apart) 1.5×10 5 human primary skin fibroblasts (PSFs) in the presence of 8 μ g/ml polybrene. After 6 days, cells were seeded on mouse embryonic fibroblast (MEF) feeders at the density of 5×10 4 cells/10-cm dish and cultured for 4 additional weeks in human ES cell medium, consisting of DMEM/F12 supplemented with 20% knockout serum replacement (KSR, Invitrogen), 2mM L-glutamine, 0.1mM nonessential amino acids, 0.1mM β-mercaptoethanol, 50U/ml penicillin, 50mg/ml streptomycin and 10ng/ml human b-FGF (R&D), before hiPSC colonies were manually picked. Karyotyping of the iPSC lines was performed at the Cell Culture Facility of the Telethon Institute of Genetics and Medicine in Naples, Italy, using standard methods.
Cardiac differentiation of hiPSCs
To generate hiPSC embryoid bodies (EBs), hiPSC colonies were dissociated into clumps using PBS containing 2.5 mg/ml trypsin (USB, Staufen, Germany), 1 mg/ml collagenase IV (Invitrogen), 20% KSR, and 1 mM CaCl 2 (10 min at 37°C) and maintained for 3 days in MEFconditioned human ES medium in low attachment plates. For spontaneous differentiation, medium was then replaced with DMEM/F12 supplemented with 20% FBS, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 0.1 mM β -mercaptoethanol, 50 U/ml penicillin, and 50 μ g/ml streptomycin, and EBs were analyzed at day 15 for expression of marker genes of the 3 different germ layers. To improve cardiac differentiation, ascorbic acid (50 μ g/ml) was added to the medium, and EBs were plated at day 7 on gelatin-coated dishes for better detection of beating foci.
For induction of human cardiac progenitors, hiPSCs were seeded on MEF feeders and, 1 day later, treated for 4 days with 10 ng/ml human BMP2 (R&D) and 1 μ M SU5402 FGF receptor inhibitor (Calbiochem, Darmstadt, Germany) in RPMI 1640 medium supplemented with 2 mM L-glutamine and 2% B27 supplement without vitamin A (Invitrogen), as described previously (Leschik et al., 2008; Moretti et al., 2010) . Conversion of human cardiac progenitors into myocytes and vascular cells (endothelial and smooth muscle cells) was induced by supplementing the culture medium with 50 μ g/ml ascorbic acid and 10 ng/ml human VEGF (R&D System).
Immunofluorescence and alkaline phosphatase activity assay.
hiPSCs (undifferentiated or differentiated) were fixed in 3.7% (vol/vol) formaldehyde and subjected to immunostaining by using the following primary antibodies: human Nanog (rabbit polyclonal, Abcam, 1:500), TRA1-81-Alexa-Fluor-488-conjugated (mouse monoclonal, BD Pharmingen, 1:20). Alexa-Fluor-488, -594, and -647 conjugated secondary antibodies specific to the appropriate species were used (Life Technologies, 1:500). Nuclei were detected with 1 µg/ml Hoechst 33528. Direct alkaline phosphatase activity was analyzed using the NBT/BCIP alkaline phosphatase blue substrate (Roche), according to the manufacturer's guidelines. Microscopy was performed using the imaging systems (DMI6000-AF6000), filter cubes and software from Leica microsystems. Images were pseudo-colored.
Mouse lines and immunofluorescence
Mef2c-AHF-Cre mice (Verzi et al., 2005) were crossed with Tbx1 +/mice (Lindsay et al., 2001 ) (Lindsay et al., 2001) to obtain Mef2c-AHF-Cre;Tbx1 +/animals, which were then crossed with Tbx1 flox/flox or Tbx1 +/mice. Animal studies were carried under the auspices of the animal protocol 257/2015-PR (licensed to the AB lab) reviewed, according to Italian regulations, by the Italian Istituto Superiore di Sanità and approved by the Italian Ministero della Salute. Pregnant females at plug day (E) 9.5 were sacrificed using CO 2 inhalation. The laboratory applies the "3Rs" principles to minimize the use of animals and to limit or eliminate suffering.
Immunofluorescence on paraffin-embedded E9.5 embryo sections was performed using an anti Cre antibody (Novagen, 69050-3, 1:1000), and an anti Isl1 antibody (Hybridoma Bank, 39.4D5s, 1:50).
Quantitative reverse transcription PCR (qRT-PCR)
Total mRNA was isolated from PSF, hiPSCs, EBs, and cardiac cells using the Stratagene Absolutely RNA kit and 1µg was used to synthesize cDNA using the High-Capacity cDNA 
Statistical analysis
All data were expressed as means ± SE from independent experiments. Differences between groups were examined for statistical analysis using a 2-tailed Student's t test. Values of P < 0.05 were considered significant.
Results and Discussion
Increased Tbx1 expression is associated with reduced histone 3 acetylation of Mef2c AHF enhancer sequence.
To understand the mechanisms by which Tbx1 represses Mef2c, we used mouse myoblast C2C12 cells undergoing muscle differentiation. We transfected a Tbx1 expression vector in these cells at day 0 and let them differentiate (Fig. 1a) . The Mef2c gene was strongly upregulated at day 3 of differentiation in control cells, but in Tbx1-transfected cells this upregulation was strongly reduced (Fig. 1b ). To exclude that this effect may be due to a delayed differentiation caused by early Tbx1 transfection, we repeated the experiment by transfecting Tbx1 after the initiation of differentiation, at day 2, and assayed Mef2c expression at day 3.
Also in this case we observed a strong reduction of Mef2c expression ( Fig. 1c ).
Tbx1 ChIP-seq data obtained on P19Cl6 cells (Fulcoli et al., 2016) and previously published q-ChIP data on C2C12 cells (Pane et al., 2012) revealed enrichment at the Mef2c anterior heart field (AHF) enhancer, as previously defined (Dodou et al., 2004) (Fig. 2a ). In particular, by comparing Tbx1 ChIP-seq data on P19Cl6 cells with histone modification data during cardiac differentiation of mouse embryonic stem cells (ESCs) (Wamstad et al., 2012) , we noted that the Tbx1-enriched region is relatively poor in H3K27Ac in ESCs but it progressively becomes H3K27Ac-rich during cardiac differentiation. Using available data from ENCODE, we also noted that the same region is acetylated in E14.5 in heart, where Tbx1 is not expressed (Fig. 2a) . These observations suggest that in this region H3 acetylation increases as differentiation progresses. Thus, we reasoned that Tbx1, directly or indirectly, might negatively regulate acetylation in this region. To test this possibility, we performed quantitative chromatin immunoprecipitation (q-ChIP) with an antibody against H3 acetylation (H3-Ac) in C2C12
cells. Results showed that Tbx1 overexpression substantially reduced H3-Ac enrichment at the Mef2c AHF enhancer (Fig. 2b) . These results suggest that Tbx1 contrasts Mef2c-AHF enhancer activity.
Loss of Tbx1 is associated with expansion of transgenic Mef2c-AHF-Cre expression in vivo.
To determine whether Tbx1 represses the activity of the Mef2c AHF enhancer in vivo, we used the transgenic Mef2c-AHF-Cre line (Verzi et al., 2005) , which carries the AHF enhancer that drives the expression of Cre recombinase. The activity of the enhancer was detected using immunofluorescence with an anti-Cre antibody on embryo sections. We tested Mef2c-AHF-Cre;Tbx1 +/+ (control) embryos and Mef2c-AHF-Cre;Tbx1 flox/embryos (homozygous null in the Mef2c-AHF-Cre expression domain, and heterozygous elsewhere). We found that at E9.0 (20 somites), Mef2c-AHF-Cre was expressed in the core mesoderm of the 1 st and 2 nd pharyngeal arches (PAs), in the cardiac outflow tract (OFT), in the SHF (mostly anterior) and in a posterior-lateral cell population of the splanchnic mesoderm at the level of the cardiac inflow tract inlet, in continuity with the SHF (Fig. 3) . Cre expression in the more anterior domains (PAs, OFT, and SHF) was comparable between control and mutant embryos (Fig. 3.. ).
However, more posteriorly, Cre expression was expanded in both heterozygous and homozygous mutants, albeit more evident in the latter (Fig. 3..) .
Increased expression of MEF2C in 22q11.2DS-derived hiPSCs upon cardiac differentiation.
To determine whether the above observations are also relevant for human cells, we have generated induced pluripotent stem cells (hiPSCs) from a 22q11.2DS patient and from an unrelated healthy donor (see cartoon in Fig. 4) . hiPSC lines were characterized as shown in Figs. 5 and 6). Two hiPSC clones were differentiated into cardiac progenitors using a previously described protocol (Leschik et al., 2008; Moretti et al., 2010) . We measured TBX1 expression and found that it peaked at day 4 of differentiation (Fig. 7a) , when cells also expressed other markers of cardiac progenitors (Fig. 7b ). 22q11.2DS-derived cell lines expressed a lower level of TBX1, as the deletion removes one copy of the gene (Fig. 7a ).
We measured the expression of MEF2C and GATA4, which is another target of Tbx1 (Liao et al., 2008; Pane et al., 2012) , by qRT-PCR at days 4, 8, and 12 of differentiation and found that both genes are up regulated in patient-derived cells at all differentiation points tested, compared to control cells ( Fig. 8a-b ).
Next, we performed q-ChIP assays on the AHF enhancer homologous region of the MEF2C gene and on the GATA4 promoter. Results demonstrated that H3Ac enrichment is significantly higher in 22q11.2DS cells compared to controls for both genes (Fig. 9 ).
Overall, our data indicate that Tbx1 functions as a transcriptional repressor of the Mef2c AHF enhancer in mouse and human cells and in vivo, in mouse embryos. In embryos, we noted that the response of the enhancer is Tbx1 dosage-dependent and is restricted to a posteriorlateral domain, indicating context-dependent regulation. The AHF enhancer integrates the actions of several critical transcription factors (Dodou et al., 2004) , e.g. Isl1, Nkx2-5, Gata4, and also Tbx1. Interpreting the combinatorial code governing its regulation is of interest for the understanding of SHF development. We have previously shown that in cultured cells, Tbx1
inhibits Gata4-mediated activation of the AHF enhancer, but not Isl1-mediated activation (Pane et al., 2012) . Interestingly, here we noted that the Mef2c-AHF-Cre expanded expression domain in mutant embryos is Isl1-negative, while most of the other Mef2c-AHF-Cre expression domains are Isl1-positive. In the future, it would be of interest to establish whether Isl1 represents a "protective factor" against Tbx1-dependent suppression.
Genome-wide data obtained in P19Cl6 cells showed that, in general, chromatin regions occupied by Tbx1 are H3K27Ac-poor (Fulcoli et al., 2016) . This may be because Tbx1 has an active role in histone de-acetylation or because H3K27Ac-poor regions are more likely to bind Tbx1. Future experiments will be aimed at establishing the mechanisms of interaction between Tbx1 and the histone acetylation or de-acetylation machineries. 
Figure Legends
Figure 3
Tbx1 regulates the Mef2c AHF enhancer in vivo.
Immunofluorescence of transverse sections of E9.0 (20 somites) embryos with the genotype indicated, using antibodies anti Cre (green) and anti Isl1 (red). The first row (a) of sections correspond to a level immediately below the outflow tract. The second row (b) is just anteriorly to the inflow tract, while the third fourth and fifth rows (c-e) correspond to the inflow tract. Note that the Cre signals in rows a and b are comparable in the three genotypes, while in rows c and d, reduced dosage of Tbx1 is associated with expansion of Cre expression.
Figure 4
Experimental design for the generation and cardiac differentiation of control and 22q11.2DS induced pluripotent stem cells (iPSCs).
Human iPSCs were generated by overexpression of retroviral transgenes for OCT3/4, SOX2 and KLF4 in primary skin fibroblasts from a 22q11.2DS patient and from an unrelated healthy donor. Two iPSCs clones from each individual were differentiated in cardiac progenitors and analyzed by quantitative RT-PCR (qRT-PCR).
Figure 5
Generation and characterization o 22q11.2DS patient-derived iPSCs.
Images of colonies from a representative 22q11.2DS iPSC clone in bright field (a) and after staining for alkaline phosphatase (AP) activity (b 
Figure 9
Acetylation of Histone 3 in MEF2C and GATA4 loci is enhanced in differentiating 22q11.2DS iPS cells.
(a,b) Localization of primer pairs (arrows) used for ChIP experiments with human cells on MEF2C and GATA4 genes. "AHF enhancer" indicates a region of high similarity with the murine AHF enhancer. For reference, we report ENCODE ChIP-seq data for H3K27Ac for two cell types, undifferentiated human embryonic stem cells (H1-hESC) and human skeletal muscle myoblasts (HSMM). The GATA4 promoter region is not acetylated in these two cell types.
(c) ChIP assays with an antibody anti-AcH3 in differentiating control and 22q11.2DSiPS cells followed by quantitative real-time PCR.
